

Prevalence of Sarcopenic Obesity and its Association with Functionality, Lifestyle, Biomarkers and Morbidities in Older Adults: the FIBRA-RJ Study of Frailty in Older Brazilian Adults

Glauca Cristina de Campos^{1,*} Roberto Alves Lourenço¹ Claudia S. Lopes¹

¹Departamento de Epidemiologia, Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, RJ, BR. ²Departamento de Medicina Interna - Faculdade de Ciencias Medicas, Universidade do Estado do Rio de Janeiro, RJ, BR.

de Campos GC, Lourenço RA, Lopes CS. Prevalence of Sarcopenic Obesity and its Association with Functionality, Lifestyle, Biomarkers and Morbidities in Older Adults: the FIBRA-RJ Study of Frailty in Older Brazilian Adults. Clinics. 2020;75:e1814

*Corresponding author. E-mail: glauciacampos@ig.com.br

OBJECTIVES: To assess the prevalence of sarcopenic obesity and its association with functionality, lifestyle, biomarkers, and morbidities in older adults.

METHODS: The study analyzed cross-sectional data from 270 older adults who participated in phase III of the Frailty in Brazilian Older People Study (Fragilidade em Idosos Brasileiros—Rio de Janeiro, FIBRA-RJ study–2013). They took part in a home interview surveying socioeconomic, demographic, lifestyle, morbidities, and functional data. Blood was collected for biochemical marker analysis and participants' body composition was determined by dual-energy X-ray absorptiometry. For women, the diagnosis of sarcopenic obesity was defined at a body fat percentage $\geq 38\%$ and appendicular skeletal muscle mass index (ASMMI) $< 5.45 \text{ kg/m}^2$. For men, a fat percentage $\geq 27\%$ and ASMMI $< 7.26 \text{ kg/m}^2$ was defined as sarcopenic obesity. Multivariate analysis was performed using a multinomial regression model (95% confidence intervals), with sarcopenic obesity as the outcome.

RESULTS: The prevalence of sarcopenic obesity was 29.3%. In the final fitted model, the variables that displayed statistically significant association with sarcopenic obesity were lower gait speed, self-reported medical diagnosis of arthrosis or arthritis, and high levels of glycemia.

CONCLUSION: The study showed a high prevalence of sarcopenic obesity in non-institutionalized older adults in Brazil. The finding that this condition was associated with modifiable risk factors may provide insights into measures directed at prevention and reduction of the risk of sarcopenic obesity in this population subgroup.

KEYWORDS: Cross-Sectional Study; Elderly; Obesity; Sarcopenic Obesity.

INTRODUCTION

The diagnosis of sarcopenic obesity (SO) considers the simultaneous presentation of high fat mass and low muscle mass; it represents the confluence between two body-composition phenotypes: sarcopenia and obesity. In recent years, obesity and sarcopenia have come to be considered as global epidemics, having a substantial impact on older adults' quality of life, mainly through the synergistic effects of these two factors.

Globally, and in Brazil, the prevalence of SO in older adults has increased in recent years (1-7). However, due to

the use of different diagnostic criteria and methods, the reported prevalence has varied considerably.

Studies using anthropometric measurements and electrical bioimpedance to diagnose SO have tended to find prevalence values ranging from 2% to 25% (8-11). Studies using dual-energy X-ray absorptiometry (DXA) have observed higher prevalence values, ranging from 2.75% to 84% (2,3,12-19). Baumgartner (17) was one of the pioneers in defining SO using DXA as a diagnostic method (20,21).

The DXA assessment of body composition is less likely to be influenced by body water content than other methods. Measurements obtained by this method has been considered as a reference standard in validation studies of methods and equations used to assess body composition. This method offers good validity and reliability and is a non-invasive technique for collecting information on various human body tissue types (22-24).

Prior studies have found an association between SO and functionality, sedentarism, biomarkers such as C-reactive protein (CRP), glucose, and albumin, and diabetes mellitus (18,20,25,26). In a study of 2,264 older adults in Korea, Ryu et al. (18) showed that engaging in moderate physical activity was inversely associated with SO.

Copyright © 2020 CLINICS – This is an Open Access article distributed under the terms of the Creative Commons License (<http://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

No potential conflict of interest was reported.

Received for publication on August 27, 2020. **Accepted for publication on** September 21, 2020

DOI: 10.6061/clinics/2020/e1814



More recently, there has been increasing interest in elucidating the relationship between biomarkers and SO (26,27). In several studies, biochemical markers, such as C-reactive protein (CRP) (26), glucose, and albumin (25,28), have been associated with SO. The association was usually two-way, but there was some evidence that high CRP and insulin resistance can predict SO (26). A high CRP level is a non-specific clinical marker of inflammation, and is associated with muscle catabolism (20,26).

SO is associated with increased morbidity, mortality, reduced quality of life, increased hospital admissions, and higher health costs (7,29). However, the related studies have used different criteria and methods, and, in Brazil, few studies used DXA (1,30-32) as a method for evaluating SO, and none have investigated its associated factors in the present study.

Accordingly, the objective of this study was to evaluate the prevalence of SO in older adults in Brazil, and to investigate its association with functionality, lifestyle, particular biomarkers, and physical morbidity.

■ MATERIAL AND METHODS

Study design and population

The methodology of the Frailty in Brazilian Older Adults study (Fragilidade em Idosos Brasileiros, seção Rio de Janeiro, FIBRA-RJ), was described elsewhere (33). Briefly, this is a three-phase cohort study, whose sample population was sourced from the client database of a health care and social security foundation. In phase I, in 2009, the baseline sample was enrolled using the following inclusion criteria: being a client of the social security foundation for at least 1 year; being 65 years or older; and residing in one of the northern neighborhoods of Rio de Janeiro City, Brazil. The exclusion criteria were: having a Mini-Mental State Examination (MMSE) score of ≤ 13 ; having an active neuropsychiatric condition; having severe hearing or sight impairment that would prevent response to the questionnaire; having a limiting gait disturbance; or being a wheelchair user or bedbound. Participants were interviewed at their homes. The sampling plan was stratified by sex and age group. An inverse sampling strategy was applied to achieve a sample size representative of each stratum, making it unnecessary to increase the calculated sample size to offset the non-response rate (33). The first phase sample comprised 847 individuals.

The data analyzed in the present study were obtained from the phase III database recorded in 2013. From the phase I sample, 136 individuals were excluded due to death and 102 individuals for the following reasons: MMSE score of ≤ 13 ; institutionalization; wheelchair user or bedbound; pacemaker user; difficulty in walking; or severe cognitive changes reported by the family. After these exclusions, 609 individuals were eligible, and attempts were made to contact them to request participation. Of these, 64 could not be located, and 143 refused to take part. Thus, 402 older adults constituted the final sample; these individuals participated in home interviews, following the phase I protocol.

For blood tests and body composition evaluation, all 402 individuals were invited to visit the clinical analysis and nutritional evaluation laboratories of Rio de Janeiro State University (Universidade do Estado do Rio de Janeiro, UERJ). Transport was offered to those with difficulty in traveling from home. Three hundred individuals agreed to proceed with the study; the blood test was performed on 297 and the DXA examination on 270 (Figure 1).

Measurements and variables

Body composition. Weight and height were measured for all participants while barefoot and wearing light clothing, using the methods described by Lohman et al. (34). Height was measured using a tape measure fixed to the wall and was recorded in millimeters, with no rounding. Weight was measured using portable digital scales (Plenna/Everest TIN-00110), with a capacity of 150 kg and accurate to 200 g, and was recorded to a tenth of a kilogram, with no rounding.

DXA was used to evaluate body composition (General Electric, model GE Lunar IDXA). Fat mass and lean mass were analyzed. The upper and lower limbs were isolated from the trunk and head by lines drawn by the software, which could then be manually adjusted with precision. Appendicular muscle mass was evaluated by means of the appendicular skeletal muscle mass index (ASMMI), obtained by adding lean mass, *i.e.*, lean tissue (kg), from the arm and leg regions, and dividing by the square of the height (meters) (35).

Dependent variable. SO was diagnosed by a combination of variables used to diagnose obesity and sarcopenia as measured by DXA. Elderly individuals were classified as obese by body fat percentage cut-off values ($\geq 38\%$ for women and $\geq 27\%$ for men) (17,36), and as sarcopenic when the ASMMI was $< 7.26 \text{ kg/m}^2$ for men, and $< 5.45 \text{ kg/m}^2$ for women (36). Accordingly, women with both a fat percentage $\geq 38\%$ and ASMMI $< 5.45 \text{ kg/m}^2$, and men with both a fat percentage $\geq 27\%$ and ASMMI $< 7.26 \text{ kg/m}^2$, were defined as having SO (17,36).

In order to evaluate the dependent variable, SO, participants were categorized as eutrophic, non-sarcopenic obese, or sarcopenic obese.

Independent variables. Factors potentially associated with SO were grouped into three groups: 1) functional variables and physical morbidities (gait speed, hand grip, instrumental activities of daily living, diabetes mellitus, and arthrosis/arthritis), 2) biomarkers (CRP, albumin, and glucose), and 3) lifestyle variables (tobacco use, daily consumption of alcohol, and regular walking for exercise).

Functional variables and physical morbidities. Gait speed was evaluated by measuring the time taken by the individual to walk 4.6 meters at their habitual pace. A chronometer was started at the moment the individual placed a foot on the starting mark and lifted the other off the ground. Individuals with gait speeds of 0.8 m/s or less were considered as displaying gait slowing (35).

Muscular strength was evaluated by taking three measurements at regular intervals of 1 minute using a hydraulic dynamometer (Jamar NC 701/42—North Coast, Rio de Janeiro, Brazil) in the dominant hand. The grip was adjusted according to the participant's sex: position 2 for women and position 3 for men. The mean value of the three measurements was calculated and analyzed with adjustment for the individual's sex and BMI. Individuals in the first performance quintile were considered to have low hand-grip strength (37).

Instrumental Activities of Daily Living (IADLs) were assessed using the Lawton scale (38), for seven day-to-day activities: using the telephone, shopping, leaving home




Figure 1 - Diagram for selecting the final sample of the FIBRA RJ-III study. *GERONLAB researchers conducted a face-to-face interview with the participant at their residence and obtained anthropometric measurements. **Visit to the Human Aging Laboratory for blood tests. ***Visit of the elderly person to the Interdisciplinary Nutritional Assessment Laboratory to assess body composition through DEXA: Exclusion=4, not found=4, refusal=123, and deceased during the study=1.

alone, preparing meals, performing domestic chores, managing finances, and taking medicines. Individuals needing help in any one activity or more were considered dependent.

Physical morbidities—diabetes mellitus and arthrosis/arthritis—were investigated by self-reporting in answer to the question: “Has a doctor ever told you that you have the following health problems: diabetes mellitus (Yes/No) and arthrosis/arthritis (Yes/No)?”.

Biomarkers. CRP levels were considered abnormal at >0.5 mg/dl; albumin was considered low at <3.5 g/dl; and glycemia was considered high at >100 mg/dl. The participant’s blood samples were collected by trained technicians, by vacuum venipuncture, after a 12-hour fast. Participants abstained from physical exercise for 24 hours before collection, and from consuming alcohol in the 72 hours before collection.

Lifestyle. The lifestyle variables examined were tobacco use (current smoker/ever smoked and stopped/never

smoked), walking for exercise (Yes/No), and consuming alcohol on a daily basis (Yes/No).

Covariables. The socioeconomic and demographic variables: age, sex, income, schooling, and race were included as covariables.

Age was recorded in years, in three age groups (65-74 years; 75-84 years; ≥ 85 years). Income source was described as retired, pensioners, and/or with other sources of income. Individual income from work, retirement benefit, or pension was recorded in minimum wages (MWs) at the time of interview and was categorized as 0-2 MWs; 2.1-5 MWs; and >5 MWs. Education was recorded in years and was categorized as illiterate, 1-5 years; 6-11 years, and ≥ 12 years. Race was categorized as white and Afro-descendent.

Statistical analysis

For descriptive analysis, absolute and relative frequencies were calculated for the categorical variables. To evaluate the dependent variable, individuals were categorized as



eutrophic, non-sarcopenic obese, and sarcopenic obese. A bivariate analysis was performed, using the chi-square test, to investigate the association between SO and the independent variables.

Subsequent multivariate analysis was performed by multinomial logistic model, which yielded crude and adjusted odds ratios (ORs) as measures of association, together with their respective 95% confidence intervals (95%CI). That model was used to identify associations of functional variables, morbidities, biochemical markers, and lifestyle with SO.

Independent variables that returned $p < 0.20$ in the bivariate analysis were included in the multivariate models. We evaluate the fit of the model using the deviance statistic and the pseudo-R of Nagelkerke. Statistical analysis was conducted using the statistical package SPSS for Windows, version 19.

Ethical considerations

The study followed the recommendations of Resolution 196/96 of the Ministry of Health's National Health Council (Conselho Nacional de Saúde), and was approved by the National Research Ethics Committee (Comissão Nacional de Ética e Pesquisa, CONEP), in opinion No. 120.700/2012. All participants signed a declaration of free and informed consent.

RESULTS

This study examined 270, predominantly female, older adults, of mean age 77.5 years (SD=5.92). The prevalence of SO was 29.3% (n=78). Most participants were white, with an income ranging from 2.1 to 5 MW, and were in the 75-84 year age group. Almost half had 6-11 years' education, while about one-third had more than 12 years' education (Table 1).

Table 2 shows the prevalence of SO, by socioeconomic, demographic, lifestyle, morbidity, biochemical marker, and functional characteristics. The prevalence of SO was markedly higher among men than among women, and among white than among Afro-descendent individuals. Less than one-third of individuals with SO had 6-11 years' education, while just more than one-third reported an income of >5 MW (Table 2).

The prevalence of SO among people with and without arthrosis/arthritis was significantly different, but was not different among those with and without DM, and was similar between those with arthrosis/arthritis and those with DM ($p < 0.0001$) (Table 2).

Among the lifestyle variables, a high prevalence of SO was observed in older adults who had stopped smoking and who drank alcohol daily, but these findings lacked statistical significance. SO was also present in more than one-quarter of older adults who did not walk for exercise, but this was not statistically significant (Table 2).

Analysis of the biomarkers showed that about one-fifth of older adults with SO also had hypoalbuminemia, about one-third had hyperglycemia, and about one-quarter had elevated CRP levels (Table 2).

In terms of functional variables, among individuals with SO, more than 30% had lower gait speed, more than one-third had reduced hand-grip strength, and about one-third were dependent according to the IADLs (Table 2).

Table 3 shows the means and standard deviations for body composition characteristics, by presence of obesity and SO. Individuals with SO had higher mean fat percentage values

Table 1 - Frequency of socioeconomic and demographic characteristics, morbidities, lifestyle, biomarkers, body composition, and functional phenotypes (FIBRA-RJ-2013).

Characteristics		N (270)	(%)
Sex	Male	81	30.0
Ethnicity	Afro-descendent	99	36.7
Income bracket (*MW)	0-2	49	19.1
	2.1-5	119	46.5
	> 5	88	34.4
Age group (years)	65-74	101	37.4
	75-84	127	47.0
	≥ 85	42	15.6
Schooling (years)	Illiterate	1	0.4
	1-5	53	19.6
	6-11	125	46.3
	> 12	91	33.7
Diabetes mellitus	Yes	68	25.3
Arthrosis/Arthritis	Yes	133	49.3
Tobacco use	Current smoker	12	4.4
	Smoked and stopped	97	35.9
	Never smoked	161	59.6
Alcohol consumption (daily)	Yes	37	13.7
Walking for exercise	Yes	64	23.7
Albumin (<3.5 mg/dl)	Deficit	22	8.2
C-reactive protein (≥0.5 mg/dl)	High	43	16.0
Glycaemia (≥ 100 mg/dl)	High	121	45.2
Body composition phenotypes	Eutrophic	70	26.4
	Obese	117	44.2
	Sarcopenic Obese	78	29.4
IADL**	Dependent	97	35.9
Gait speed	≤ 0.8m/s	118	43.9
Hand grip	Low	69	26.3

*MW—Minimum Wages; **IADL—Instrumental Activities of Daily Living.

than eutrophic individuals ($p < 0.001$). The percentage of fat in obese individuals was exceeded when wishing with sarcopenic obsession. Individuals with SO also had lower mean muscular mass index values than obese individuals ($p < 0.001$).

Table 4 states the crude and adjusted ORs for the associations between the independent variables (functional, morbidity, lifestyle, and biomarker) and SO. The crude analyses showed that lower gait speed, daily consumption of alcohol, and hyperglycemia displayed significant associations with SO. In the final model, adjusted by the demographic and socioeconomic variables, lower gait speed, arthrosis/arthritis, and hyperglycemia were significantly associated with SO.

In Table 5, the crude and adjusted ORs for the associations between the independent variables and obesity are stated. In the final model, adjusted by the demographic and socioeconomic variables, lower gait speed, arthrosis/arthritis, and hyperglycemia were significantly associated with obesity.

DISCUSSION

This study found a high prevalence of SO and obesity among older adults in Brazil. These results corroborate other Brazilian and international studies (1,16,18,26,27,30). The prevalence of SO in Brazilian studies have ranged from 19.6% to 34.2% (30,32,39,40). Globally, studies of non-institutionalized older adults have reported an SO prevalence ranging from 2.1% to 94% (14,15,19,40,41). In Brazil, a cross-sectional study of 272 older women by Silva et al. (30) found a prevalence of SO of 34.2%, based on DXA evaluations (30).

**Table 2** - Prevalence of sarcopenic obesity, by sociodemographic and economic characteristics, lifestyle, morbidities, and biochemical and functional markers (FIBRA-RJ-2013).

Variables		Eutrophy		Obesity		Sarcopenic obesity		p-value
		N	(%)	N	(%)	N	(%)	
Sex	Female	46	25	111	60.3	27	14.7	0.0001
	Male	24	29.60	6	7.4	51	63	
Ethnicity	White	39	23.35	69	41.3	59	35.33	0.021
	Afro-descendant	31	31.63	48	48.98	19	19.39	
Income bracket (*MW)	0-2	8	16.67	22	45.83	18	37.50	0.010
	2.1-5	30	25.86	60	51.72	26	22.41	
	> 5	29	33.33	26	29.89	32	36.78	
Age group (years)	65-74	23	23.00	50	50.00	27	27.00	0.609
	75-84	34	27.42	52	41.94	38	30.65	
	≥ 85	13	31.71	15	36.59	13	31.71	
Schooling (years)	Illiterate	0	0.00	1	100.00	0	0.00	0.254
	1-5	14	28.00	26	52.00	10	20.00	
	6-11	29	23.39	59	47.58	36	29.03	
	≥ 12	27	30.00	31	34.44	32	35.56	
Diabetes Mellitus	Yes	17	25.00	36	52.94	15	22.06	0.202
	No	53	27.04	81	41.33	62	31.63	
Arthrosis/Arthritis	Yes	26	19.7	76	57.6	30	22.7	0.000
	No	44	33.1	41	30.8	48	36.1	
Tobacco use	Yes	4	33.33	4	33.33	4	33.33	0.020
	No	40	25.3	82	51.9	36	22.8	
	Smoked and stopped	26	27.4	31	32.6	38	40.0	
Daily consumption of alcohol	Yes	7	18.92	12	32.43	18	48.65	0.022
	No	63	27.63	105	46.05	60	26.32	
Walking for exercise	Yes	19	30.16	19	30.16	25	39.68	0.029
	No	51	25.25	98	48.51	53	26.24	
Albumin	Normal	69	28.5	101	41.7	72	29.8	0.007
	Deficit	1	4.8	16	76.2	4	19.0	
C-reactive protein	Normal	63	28.6	91	41.4	66	30.0	0.061
	High	7	16.3	26	60.5	10	23.3	
Glycemia	Normal	48	33.8	57	40.1	37	26.1	0.017
	High	22	18.2	60	49.6	39	32.2	
Gait speed	≤ 0.8m/s	20	17.4	62	53.9	33	28.7	0.004
	> 0.8m/s	50	33.6	54	36.2	45	30.2	
Hand grip	Low	15	21.7	29	42	25	36.2	0.320
	Normal	55	28.1	88	44.9	53	27.0	
IADL**	Independent	47	27.6	76	44.7	47	27.6	0.820
	Dependent	23	24.2	41	43.2	31	32.6	

* MW—Minimum Wage; **IADL—Instrumental Activities of Daily Living.

Table 3 - Measures and standard deviation of body composition characteristics, by body composition phenotypes and anthropometry (FIBRA-RJ-2013).

Body Composition and Anthropometry	Obesity			Sarcopenic Obesity			Total			p-value
	N	Mean	SD	N	Mean	SD	N	Mean	SD	
Fat Percentage (%)	117	44.9	3.7	78	35.6	4.5	265	38.5	7.5	<0.001
ASMMI (Kg/m ²)*	117	7.5	1.7	78	5.1	0.8	265	5.9	2.0	<0.001
Weight (Kg)	117	73.6	12.5	78	67.4	12.6	265	68.0	13.4	<0.001
Waist Circumference (cm)	117	102.5	10.5	78	96.8	8.9	265	96.6	12.0	<0.001

*ASMMI—Appendicular Skeletal Muscle Mass Index.

A cross-sectional study of 306 older adults in Spain found a prevalence of SO of 25% (10).

The present study found a higher prevalence of SO among men (65.3%) than among women (34.6%). This was a similar trend to that found by Batsis et al. (41), in a cross-sectional study in the United States by the National Health and Nutrition Examination Survey III—1999-2004. In a sub-sample of 4,984 non-institutionalized older adults of both sexes, aged 60 years or more, using cut-off points proposed by the Foundation for the National Institutes of Health, they observed a prevalence of SO, as evaluated by appendicular skeletal

muscle mass, of 27.8% in men and 19.3% in women. However, contradictory results were observed in the study (19) using data from the National Health and Nutrition Examination Survey (1999-2004) for 4,984 older adults in the United States, using different definitions from six studies (4,5,42-45) and different diagnostic criteria for SO. In that study, they found widely differing prevalence values for SO, which were often higher among women, ranging from 3.6% to 94.0%, while among the men the values varied from 4.4% to 84.0%.

Thus, the prevalence of SO is not yet clearly established and can vary by a factor of as much as 26, mainly because of

**Table 4** - Crude and adjusted odds ratios (OR) and respective 95% confidence intervals (95%CI) for the association between sarcopenic obesity and functional variables and morbidities, lifestyle and biomarkers (FIBRA-RJ -2013).

Variables	OR (95%CI)	Sarcopenic Obesity			
		Model 1 Adjusted OR (95%CI)	Model 2 Adjusted OR (95%CI)	Model 3 Adjusted OR (95%CI)	Final Model Adjusted OR (95%CI)
Gait speed					
> 0.8 m/s	1	1			1
≤ 0.8 m/s	1.83 (0.92-3.64)	2.01 (0.94-4.32)			2.43 (1.09-5.41)
Arthrosis					
No	1	1			1
Yes	1.05 (0.54-2.05)	2.05 (0.92-4.53)			2.43 (1.05-5.63)
Diabetes mellitus					
No	1	1			1
Yes	0.75 (0.34-1.65)	0.69 (0.29-1.67)			0.52 (0.19-1.37)
Smoking					
Never smoked	1		1		1
Smoker	1.11 (0.25-4.77)		0.67 (0.13-3.51)		0.23 (0.03-1.75)
Smoked and stopped	1.62 (0.82-3.18)		0.94 (0.43-2.08)		0.75 (0.31-1.76)
Daily drinker					
No	1		1		1
Yes	2.70 (1.05-6.92)		2.29 (0.81-6.46)		2.63 (0.84-8.20)
Walks					
Yes	1		1		1
No	0.79 (0.38-1.60)		0.94 (0.42-2.09)		0.86 (0.36-2.02)
Albumin					
Normal	1			1	1
Deficit	3.83 (0.41-35.15)			7.24 (0.72-72.85)	5.70 (0.54-59.89)
C-Reactive Protein					
Normal	1			1	1
High	1.36 (0.48-3.80)			1.38 (0.45-4.19)	1.22 (0.37-4.02)
Glycemia					
Normal	1			1	1
High	2.30 (1.17-4.52)			2.15 (1.02-4.55)	3.14 (1.34-7.32)

Model 1—Block of functional variables and morbidities (gait speed, arthrosis and diabetes mellitus) + adjusted for sociodemographic and economic variables (sex, income bracket and ethnicity).

Model 2—Block of lifestyle variables (tobacco use, daily consumption of alcohol and walking for exercise) + adjusted for sociodemographic and economic variables.

Model 3—Block of biochemical marker variables (glycaemia, albumin and C-reactive protein) + adjusted for sociodemographic and economic variables.

Model 4—Final; Functional variables and morbidities, lifestyle, biochemical markers + adjusted for sociodemographic and economic variables.

the use of different evaluation methods, criteria, and cut-off points applied to determine muscle mass and fat mass (19). This variability underlines the need to establish diagnostic criteria and cut-off points in order to build a consensus in the scientific literature (23). In addition, ethnic differences may influence the prevalence of SO, given that oriental populations have less muscle mass and fat mass than western populations (46).

Moon et al. (6), in a study of 1,583 older adults in Korea between 2008 and 2010, found a lower SO prevalence: 7.8% for men and 9.6% for women. Moreover, Kim et al. (26) analyzed baseline data for 493 older adults from the Korean Sarcopenic Obesity Study (KSOS) and found a prevalence of SO of 17.8% for men and 24.9% for women.

It has been suggested that obesity can lead to sarcopenia, and *vice versa* (46-48). The underlying mechanism is related to the production of substances in fatty tissue, such as tumor necrosis factor and leptin, which influence insulin resistance, reduction of energy metabolism, and secretion of growth hormone and proinflammatory cytokines, leading to progressive muscle mass loss and body fat increase, particularly by fatty infiltration of muscle (47). Muscle with high levels of infiltrated fat may be more inflamed than fat-free muscle, suggesting a connection between fat mass gain, and muscles with increased triglycerides and inflammation (47,49). Increased adiposity leads to chronic subclinical

inflammation, which fosters muscle catabolism and can lead to sarcopenia (50).

Thus, the results of this study, which showed a high prevalence of obesity (44.2%) among non-institutionalized older adults, can serve as an alert to the greater risk of such older adults developing SO in the near future. The prevalence of SO and obesity is probably associated with the specific characteristics of our sample, which included older individuals and mostly women. Indeed, in other studies, the proportion of SO and obesity increased with age, most likely due to hormone-related body composition changes, reaching higher values in individuals over 75 years of age.

The results of this study confirm the associations of SO with gait speed, hyperglycemia, and arthrosis, as reported in international studies (5,51). Lower gait speed is an important indicator of functional impairment in older adults, and this study found that older adults with reduced gait speed were twice as likely to display SO. A study by Chang et al. (9), in Taiwan examined data for 2,629 older adults from the Sarcopenia and Translational Ageing Research in Taiwan (START) survey, to evaluate the association between functionality and body composition. They found an association between lower gait speed and SO ($p < 0.005$). Moreira et al. (52), in a cross-sectional study of 491 participants in Parnamirim, Brazil, observed that variables relating to physical (functional) performance displayed statistically significant

**Table 5** - Crude and adjusted odds ratios (OR) and respective 95% confidence intervals (95%CI) for the association between obesity and functional variables and morbidities, lifestyle and biomarkers (FIBRA-RJ -2013).

Variables	OR (95%CI)	Obesity			Final Model Adjusted OR (95%CI)
		Model 1 Adjusted OR (95%CI)	Model 2 Adjusted OR (95%CI)	Model 3 Adjusted OR (95%CI)	
Gait speed					
> 0.8 m/s	1	1			1
≤ 0.8 m/s	2.87 (1.52-5.44)	2.01 (0.94-4.32)			3.12 (1.45-6.67)
Arthrosis					
No	1	1			1
Yes	3.13 (1.69-5.80)	2.05 (0.92-4.53)			2.54 (1.20-5.39)
Diabetes mellitus					
No	1	1			1
Yes	1.38 (0.70-2.71)	0.69 (0.29-1.67)			1.09 (0.42-2.81)
Smoking					
Never smoked	1		1		1
Smoker	0.48 (0.11-2.05)		0.40 (0.08-1.86)		0.33 (0.06-1.73)
Smoked and stopped	0.58 (0.30-1.10)		0.90 (0.42-1.91)		0.80 (0.35-1.83)
Daily drinker					
No	1		1		1
Yes	1.02 (0.38-2.74)		2.36 (0.75-7.43)		2.98 (0.89-9.97)
Walks					
Yes	1		1		1
No	1.92 (0.93-3.94)		1.36 (0.60-3.10)		1.16 (0.48-2.78)
Albumin					
Normal	1			1	1
Deficit	10.93 (1.41-84.34)			8.55 (1.05-69.35)	6.23 (0.72-53.74)
C-Reactive Protein					
Normal	1			1	1
High	2.57 (1.05-6.28)			1.71 (0.64-4.58)	1.76 (0.63-4.93)
Glycemia					
Normal	1			1	1
High	2.29 (1.23-4.27)			2.70 (1.32-5.55)	3.09 (1.33-7.14)

Model 1—Block of functional variables and morbidities (gait speed, arthrosis and diabetes mellitus)+ adjusted for sociodemographic and economic variables (sex, income bracket and ethnicity).

Model 2—Block of lifestyle variables (tobacco use, daily consumption of alcohol and walking for exercise) + adjusted for sociodemographic and economic variables.

Model 3—Block of biochemical marker variables (glycaemia, albumin and C-reactive protein)+ adjusted for sociodemographic and economic variables.

Model 4—Final; Functional variables and morbidities, lifestyle, biochemical markers + adjusted for sociodemographic and economic variables.

association with SO, although there was no statistical significance to the association between gait speed and SO. This vicious cycle of functional incapacity and slower gait leads to a reduction in overall energy expenditure, reduced muscle mass, and increased fat mass in older adults.

Our findings in relation to elevated glycaemia were in agreement with the findings of the study in Korea by Hwang et al. (51), which examined data from the Fourth Korea National Health and Nutrition Examination Survey (2009), a population survey of 2,221 older adults. They found that older adults with hyperglycemia had higher odds of developing SO. Santos et al. (1), in a cross-sectional study in Brazil, examined 149 older women and found a positive correlation between glucose levels and SO ($p < 0.05$).

It remains unclear whether the presence of arthrosis/arthritis precedes SO or whether individuals with SO are at higher risk of developing arthritis/arthritis. The possibility of bidirectionality between such events should not be discarded as it is quite plausible. However, we found no other study that has evaluated the role of arthrosis/arthritis in the development of SO. Tyrovolas et al. (8) analyzed data from the Collaborative Research on Ageing in Europe (COURAGE) Survey and the World Health Organization Study on Global Ageing (SAGE), which comprised 18,363 older adults from several different geographical regions of the world, between 2007 and 2012. They observed that older

adults with a chronic disease were 1.8 times more likely to develop SO.

This study had some limitations. Its cross-sectional design did not enable temporal or causal associations to be shown, leading to the possibility of reverse causation among the findings. This possibility cannot be excluded, given the bidirectionality of the phenomena studied. Another limitation involved the use of walking as physical exercise to assess the physical activity of the participants. This assessment is insufficient to assess the set of physical activities that are performed, and thus may have led to underestimation of this parameter. Additionally, there may have been information bias resulting from the self-reported physical morbidity data. The scarcity of studies and the great variability of diagnostic methods and criteria for SO placed limitations on data comparability. Moreover, the FIBRA-RJ study involves a closed cohort. This fact prevented the sample from being recomposed after losses occurred during the follow-up and exclusions during data collection. Despite these limitations, the specificities of the FIBRA-RJ sample has the advantage in terms of providing knowledge about the body composition phenotypes present in the elderly population.

To the best of our knowledge, no previous study had evaluated the prevalence of SO and its associations with functionality, lifestyle, biomarkers, and physical morbidity in Brazil, using the DXA method. Data quality was assured by



team training, data quality supervision and control immediately upon completion of the data collection protocols, and prompt correction of any errors. Lastly, evaluation of body composition by the DXA method, which is considered to be a reference method, provided greater precision and validity to the study findings.

CONCLUSION

In summary, this study revealed a high prevalence of obesity and SO among older adults in Brazil. The high prevalence of both these two body composition phenotypes are cause for concern, because obese older adults can become sarcopenic obese. The finding that slower gait, hyperglycemia, and arthrosis are associated with the presence of SO underscores the possibility that early intervention and prevention of these modifiable risk factors can assist in preventing obesity and SO in older adults.

Despite limited data comparability due to cultural and racial differences, and diversity in cut-off points and diagnostic criteria, the results of various different studies reinforce the association between lower gait speed, hyperglycemia, and SO in older adults. To improve research in this field and ensure better data comparability, it is of prime importance that consensus on the diagnosis of SO be established.

ACKNOWLEDGMENTS

The Frailty in Brazilian Older Adults study (Estudo da Fragilidade em Idosos Brasileiros, FIBRA-Seção RJ) was financed by the Conselho Nacional de Pesquisa (CNPq)—process No. 555087/2006-9—and by the Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)—process No. E-26/171.469/2006.

AUTHOR CONTRIBUTIONS

Campos GC contributed with significant participation in the study design, data collection, analysis, interpretation of data and preparation of the article. Lourenço RA contributed with significant participation in the study design, preparation or revision of the manuscript and approval of the final version of the manuscript for publication. Lopes CS contributed with significant participation in the study design, preparation and review of the analysis and manuscript and approval of the final version for publication.

REFERENCES

1. dos Santos EP, Gadelha AB, Safons MP, Nóbrega OT, Oliveira RJ, Lima RM. Sarcopenia and sarcopenic obesity classifications and cardiometabolic risks in older women. *Arch Gerontol Geriatr*. 2014;59(1):56-61. <https://doi.org/10.1016/j.archger.2014.03.012>
2. Kohara K. Sarcopenic obesity in aging population: current status and future directions for research. *Endocrine*. 2014;45(1):15-25. <https://doi.org/10.1007/s12020-013-9992-0>
3. Kim YS, Lee Y, Chung YS, Lee DJ, Joo NS, Hong D, et al. Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys. *J Gerontol A Biol Sci Med Sci*. 2012;67(10):1107-13. <https://doi.org/10.1093/gerona/gls071>
4. Bouchard DR, Dionne JJ, Brochu M. Sarcopenic/obesity and physical capacity in older men and women: data from the Nutrition as a Determinant of Successful Aging (NuAge)-the Quebec longitudinal Study. *Obesity*. 2009;17(11):2082-8. <https://doi.org/10.1038/oby.2009.109>
5. Levine ME, Crimmins EM. The impact of insulin resistance and inflammation on the association between sarcopenic obesity and physical functioning. *Obesity*. 2012;20(10):2101-6. <https://doi.org/10.1038/oby.2012.20>
6. Moon JH, Kong MH, Kim HJ. Implication of Sarcopenia and Sarcopenic Obesity on Lung Function in Healthy Elderly: Using Korean National Health and Nutrition Examination Survey. *J Korean Med Sci*. 2015;30(11):1682-8. <https://doi.org/10.3346/jkms.2015.30.11.1682>
7. Tian S, Xu Y. Association of sarcopenic obesity with the risk of all-cause mortality: A meta-analysis of prospective cohort studies. *Geriatr Gerontol Int*. 2016;16(2):155-66. <https://doi.org/10.1111/ggi.12579>
8. Tyrovolas S, Koyanagi A, Olaya B, Ayuso-Mateos JL, Miret M, Chatterji S, et al. Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi-continent study. *J Cachexia Sarcopenia Muscle*. 2016;7(3):312-21. <https://doi.org/10.1002/jcsm.12076>
9. Chang CI, Huang KC, Chan DC, Wu CH, Lin CC, Hsiung CA, et al. The impacts of sarcopenia and obesity on physical performance in the elderly. *Obes Res Clin Pract*. 2015;9(3):256-65. <https://doi.org/10.1016/j.orcp.2014.08.003>
10. Muñoz-Arribas A, Mata E, Pedrero-Chamizo R, Espino L, Gusi N, Villa G, et al. Obesidad sarcopénica y condición física en octogenarios; proyecto multi-céntrico EXERNET [Sarcopenic obesity and physical fitness in octogenarians: the multi-center EXERNET Project]. *Nutr Hosp*. 2013;28(6):1877-83.
11. Lu CW, Yang KC, Chang HH, Lee LT, Chen CY, Huang KC. Sarcopenic obesity is closely associated with metabolic syndrome. *Obes Res Clin Pract*. 2013;7(4):e301-7. <https://doi.org/10.1016/j.orcp.2012.02.003>
12. Kemmler W, von Stengel S, Engelke K, Sieber C, Freiberger E. Prevalence of sarcopenic obesity in Germany using established definitions: Baseline data of the FORMOSA study. *Osteoporos Int*. 2016;27(1):275-81. <https://doi.org/10.1007/s00198-015-3303-y>
13. Meng P, Hu YX, Fan L, Zhang Y, Zhang MX, Sun J, et al. Sarcopenia and sarcopenic obesity among men aged 80 years and older in Beijing: prevalence and its association with functional performance. *Geriatr Gerontol Int*. 2014;14 Suppl 1:29-35. <https://doi.org/10.1111/ggi.12211>
14. Lim S, Kim JH, Yoon JW, Kang SM, Choi SH, Park YJ, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLOSHA). *Diabetes Care*. 2010;33(7):1652-4. <https://doi.org/10.2337/dc10-0107>
15. Rolland Y, Lauwers-Cances V, Cristini C, Abellan van Kan G, Janssen I, Morley JE, et al. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l'Osteoporose) Study. *Am J Clin Nutr*. 2009;89(6):1895-900. <https://doi.org/10.3945/ajcn.2008.26950>
16. Aubertin-Leheudre M, Lord C, Goulet ED, Khalil A, Dionne JJ. Effect of sarcopenia on cardiovascular disease risk factors in obese postmenopausal women. *Obesity*. 2006;14(12):2277-83. <https://doi.org/10.1038/oby.2006.267>
17. Baumgartner RN. Body composition in healthy aging. *Ann N Y Acad Sci*. 2000;904:437-48. <https://doi.org/10.1111/j.1749-6632.2000.tb06498.x>
18. Ryu M, Jo J, Lee Y, Chung YS, Kim KM, Baek WC. Association of physical activity with sarcopenia and sarcopenic obesity in community-dwelling older adults: the Fourth Korea National Health and Nutrition Examination Survey. *Age Ageing*. 2013;42(6):734-40. <https://doi.org/10.1093/ageing/aft063>
19. Batsis JA, Barre LK, Mackenzie TA, Pratt SI, Lopez-Jimenez F, Bartels SJ. Variation in the prevalence of sarcopenia and sarcopenic obesity in older adults associated with different research definitions: dual-energy X-ray absorptiometry data from the National Health and Nutrition Examination Survey 1999-2004. *J Am Geriatr Soc*. 2013;61(6):974-80. <https://doi.org/10.1111/jgs.12260>
20. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. *Curr Opin Clin Nutr Metab Care*. 2008;11(6):693-700. <https://doi.org/10.1097/MCO.0b013e328312c37d>
21. Kim TN, Choi KM. Sarcopenia: definition, epidemiology, and pathophysiology. *J Bone Metab*. 2013;20(1):1-10. <https://doi.org/10.11005/jbm.2013.20.1.1>
22. Castro EA, Lima L, Amaral JF, Cerqueira M, Doimo LA. Comparação entre equações estimativas e DXA para avaliação da gordura corporal em mulheres não sedentárias. *Motricidade*. 2012;8(Supl. 2):348-56.
23. de Souza RG, Gomes AC, Prado CM, Mota JF. Métodos de análise da composição corporal em adultos obesos. *Rev Nutr*. 2014;27(5):569-83. <https://doi.org/10.1590/1415-52732014000500006>
24. Gupta N, Balasekaran G, Victor Govindaswamy V, Hwa CY, Shun LM. Comparison of body composition with bioelectric impedance (BIA) and dual energy X-ray absorptiometry (DEXA) among Singapore Chinese. *J Sci Med Sport*. 2011;14(1):33-5. <https://doi.org/10.1016/j.jsams.2010.04.005>
25. Donini LM, Poggiogalle E, Migliaccio S, Pinto A, Lubrano C, Lenzi A. Sarcopenic obesity: correlation with clinical, functional, and psychological status in a rehabilitation setting. *Food Nutr Sci*. 2014;5(20):2020.
26. Kim TN, Park MS, Lim KI, Choi HY, Yang SJ, Yoo HJ, et al. Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. *Clinical endocrinology*. 2013;78(4):525-32. <https://doi.org/10.1111/j.1365-2265.2012.04433.x>
27. Batsis JA, Mackenzie TA, Jones JD, Lopez-Jimenez F, Bartels SJ. Sarcopenia, sarcopenic obesity and inflammation: Results from the 1999-2004 National Health and Nutrition Examination Survey. *Clin Nutr*. 2016;35(6):1472-83. <https://doi.org/10.1016/j.clnu.2016.03.028>



28. Hara N, Iwasa M, Sugimoto R, Mifuji-Moroka R, Yoshikawa K, Terasaka E, et al. Sarcopenia and Sarcopenic Obesity Are Prognostic Factors for Overall Survival in Patients with Cirrhosis. *Intern Med.* 2016;55(8):863-70. <https://doi.org/10.2169/internalmedicine.55.5676>
29. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. *J Am Geriatr Soc.* 2004;52(1):80-5. <https://doi.org/10.1111/j.1532-5415.2004.52014.x>
30. Silva AO, Karnikowski MG, Funghetto SS, Stival MM, Lima RM, de Souza JC, et al. Association of body composition with sarcopenic obesity in elderly women. *Int J Gen Med.* 2013;6:25-9. <https://doi.org/10.2147/IJGM.S36279>
31. Dutra MT. Associação entre sarcopenia e obesidade sarcopênica com variáveis inflamatórias em mulheres idosas. 2013.
32. Neto LS, Karnikowski MG, Tavares AB, Lima RM. Associação entre sarcopenia, obesidade sarcopênica e força muscular com variáveis relacionadas de qualidade de vida em idosas. *Rev. bras. fisioter.* 2012;16(5): 360-7.
33. Lourenço RA, Sanchez MA, Moreira VG, Ribeiro PC, Perez M, Campos GC, et al. Fragilidade em Idosos Brasileiros-FIBRA-RJ: metodologia de pesquisa dos estudos de fragilidade, distúrbios cognitivos e sarcopenia. *Revista HUPE.* 2015;14(4).
34. Lohman TG, Roche AF. Anthropometric standardization reference manual. Human kinetics books. 1988.
35. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing.* 2010;39(4):412-23. <https://doi.org/10.1093/ageing/afq034>
36. Baumgartner RN, Wayne SJ, Waters DL, Janssen I, Gallagher D, Morley JE. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. *Obes Res.* 2004;12(12):1995-2004. <https://doi.org/10.1038/oby.2004.250>
37. Moreira VG, Lourenço RA. Prevalence and factors associated with frailty in an older population from the city of Rio de Janeiro, Brazil: the FIBRA-RJ Study. *Clinics.* 2013;68(7):979-85. [https://doi.org/10.6061/clinics/2013\(07\)15](https://doi.org/10.6061/clinics/2013(07)15)
38. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist.* 1969;9(3):179-86. https://doi.org/10.1093/geront/9.3.Part_1.179
39. Oliveira RJ, Bottaro M, Júnior JT, Farinatti PT, Bezerra LA, Lima RM. Identification of sarcopenic obesity in postmenopausal women: a cutoff proposal. *Braz J Med Biol Res.* 2011;44(11):1171-6. <https://doi.org/10.1590/S0100-879X2011007500135>
40. Gadelha AB, Dutra MT, de Oliveira RJ, Safons MP, Lima RM. Association among strength, sarcopenia and sarcopenic obesity with functional performance in older women/Associação entre força, sarcopenia e obesidade sarcopênica com o desempenho funcional de idosas. *Motricidade.* 2014; 10(3):31-40. [https://doi.org/10.6063/motricidade.10\(3\).2775](https://doi.org/10.6063/motricidade.10(3).2775)
41. Batsis JA, Mackenzie TA, Lopez-Jimenez F, Bartels SJ. Sarcopenia, sarcopenic obesity, and functional impairments in older adults: National Health and Nutrition Examination Surveys 1999-2004. *Nutr Res.* 2015; 35(12):1031-9. <https://doi.org/10.1016/j.nutres.2015.09.003>
42. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. *Am J Epidemiol.* 1998;147(8):755-63. <https://doi.org/10.1093/oxfordjournals.aje.a009520>
43. Davison KK, Ford ES, Cogswell ME, Dietz WH. Percentage of body fat and body mass index are associated with mobility limitations in people aged 70 and older from NHANES III. *J Am Geriatr Soc.* 2002;50(11):1802-9. <https://doi.org/10.1046/j.1532-5415.2002.50508.x>
44. Zoico E, Di Francesco V, Guralnik JM, Mazzali G, Bortolani A, Guariento S, et al. Physical disability and muscular strength in relation to obesity and different body composition indexes in a sample of healthy elderly women. *Int J Obes Relat Metab Disord.* 2004;28(2):234-41. <https://doi.org/10.1038/sj.ijo.0802552>
45. Kim TN, Yang SJ, Yoo HJ, Lim KI, Kang HJ, Song W, et al. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study. *Int J Obes.* 2009;33(8):885-92. <https://doi.org/10.1038/ijo.2009.130>
46. Kim TN, Park MS, Ryu JY, Choi HY, Hong HC, Yoo HJ, et al. Impact of visceral fat on skeletal muscle mass and vice versa in a prospective cohort study: the Korean Sarcopenic Obesity Study (KSOS). *PLoS One.* 2014; 9(12):e115407. <https://doi.org/10.1371/journal.pone.0115407>
47. Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco V. Sarcopenic obesity: a new category of obesity in the elderly. *Nutr Metab Cardiovasc Dis.* 2008;18(5):388-95. <https://doi.org/10.1016/j.numecd.2007.10.002>
48. Roubenoff R, Hughes VA. Sarcopenia: current concepts. *J Gerontol A Biol Sci Med Sci.* 2000;55(12):M716-24. <https://doi.org/10.1093/gerona/55.12.M716>
49. Sakuma K, Yamaguchi A. Sarcopenic obesity and endocrinal adaptation with age. *Int J Endocrinol.* 2013;2013:204164. <https://doi.org/10.1155/2013/204164>
50. Cauley JA. An Overview of Sarcopenic Obesity. *J Clin Densitom.* 2015; 18(4):499-505. <https://doi.org/10.1016/j.jocd.2015.04.013>
51. Hwang B, Lim JY, Lee J, Choi NK, Ahn YO, Park BJ. Prevalence rate and associated factors of sarcopenic obesity in Korean elderly population. *J Korean Med Sci.* 2012;27(7):748-55. <https://doi.org/10.3346/jkms.2012.27.748>
52. Moreira MA, Zunzunegui MV, Vafaei A, da Câmara SM, Oliveira TS, Maciel AC. Sarcopenic obesity and physical performance in middle aged women: a cross-sectional study in Northeast Brazil. *BMC Public Health.* 2016;16:43. <https://doi.org/10.1186/s12889-015-2667-4>